Table 1: Modes of HCV Transmission
Table 2: Symptoms of Acute and Chronic HCV Infection
Table 3: Risk Factors and Comorbidities Associated with HCV Infection
Table 4: 9MM, Anti-HCV+ Total Prevalence from 1988–2015
Table 5: Hepatitis C Virus Genotype Description
Table 6: 9MM, Sources Used to Forecast Anti-HCV+ Total Prevalent Cases
Table 7: 9MM, Sources Used to Forecast HCV RNA+ Total Prevalent Cases
Table 8: 9MM, Sources Used to Forecast Anti-HCV+ Total Prevalent Cases by HCV Genotypes
Table 9: 9MM, Sources Used to Forecast HCV/HIV Co-Infection Cases Among Anti-HCV+ Total Prevalent Cases
Table 10: 9MM, Sources Used to Forecast HCV/HBV Co-Infection Cases Among Anti-HCV+ Total Prevalent Cases
Table 11: 9MM, Sources Used to Forecast Anti-HCV+ Diagnosed Prevalent Cases
Table 12: 9MM, Sources Used to Forecast HCV RNA+ Diagnosed Prevalent Cases
Table 13: 9MM, Sources Used for Anti-HCV+ Diagnosed Prevalent Cases by Liver Cirrhosis Status
Table 14: 9MM, Sources Not Used in Epidemiological Forecast for Anti-HCV+ Total Prevalent Cases
Table 15: 9MM, Anti-HCV+ Total Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015–2025
Table 16. 9MM, Anti-HCV+ Total Prevalent Cases, by Age, Both Sexes, N (Row %), 2015
Table 17: 9MM, Anti-HCV+ Total Prevalent Cases, by Sex, All Ages, N (Row %), 2015
Table 18: 9MM, Anti-HCV+ Total Prevalent Cases, by HCV Genotype, All Ages, N (Row %), Both Sexes, 2015
Table 19: 9MM, HCV RNA+ Total Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015–2025
Table 20. 9MM, HCV RNA+ Total Prevalent Cases, by Age, Both Sexes, N (Row %), 2015
Table 21: 9MM, HCV RNA+ Total Prevalent Cases, by Sex, All Ages, N (Row %), 2015
Table 22: 9MM, Anti-HCV+ Diagnosed Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015–2025
Table 23: 9MM, Age-Specific Anti-HCV+ Diagnosed Prevalent Cases, Both Sexes, N (Row %), 2015
Table 24: 9MM, Anti-HCV+ Diagnosed Prevalent Cases, by Sex, All Ages, N (Row %), 2015
Table 25: 9MM, HCV RNA+ Diagnosed Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015–2025
Table 26: 9MM, Age-Specific HCV RNA+ Diagnosed Prevalent Cases, Both Sexes, N (Row %), 2015
Table 27: 9MM, HCV RNA+ Diagnosed Prevalent Cases, by Sex, All Ages, N (Row %), 2015
Table 28: HCV Genotypes Prevalent in the 9MM
Table 29: General Standard of Care by HCV Genotype in 2015
Table 30: Treatment Guidelines for Hepatitis C
Table 31: Country Profile – US
Table 32: Recommended Treatment Options for Treatment-Naïve Patients in the US, 2016
Table 33: Country Profile – 5EU
Table 34: Recommended Treatment Options for Treatment-naïve Patients in the 5EU, 2016
Table 35: Country Profile – Japan
Table 36: Country Profile – Brazil
Table 37: Country Profile – China
Table 38: Leading Treatments for Hepatitis C, 2016
Table 39: Harvoni – Clinical Trials Supporting Regulatory Approval
Table 40: Product Profile – Harvoni
Table 41: Key Clinical Trials of Gilead’s Harvoni
Table 42: Safety of Harvoni – Most Common AEs
Table 43: Harvoni SWOT Analysis, 2016
Table 44: Global Sales Forecasts ($m) for Harvoni, 2015–2025
Table 45: Viekira Pak and Technivie – Key Clinical Trials Supporting Regulatory Approval
Table 46: Product Profile – Viekira Pak and Technivie
Table 47: Efficacy of Viekira Pak and Technivie – SVR12, Key Phase III and Phase II Studies
Table 48: Safety of Viekira Pak and Technivie – Most Common AEs
Table 49: Viekira Pak and Technivie SWOT Analysis, 2016
Table 50: Global Sales Forecast ($m) for Viekira Pak, 2015–2025
Table 51: Zepatier – Key Clinical Trials Supporting Regulatory Approval
Table 52: Product Profile – Zepatier
Table 53: Efficacy of Zepatier – SVR12, Key Phase III and Phase II Clinical Trials
Table 54: Treatment-Emergent Amino Acid Substitutions Among Virologic Failures of Zepatier
Table 55: Safety of Zepatier – Most Common AEs
Table 56: Zepatier SWOT Analysis, 2016
Table 57: Global Sales Forecasts ($m) for Zepatier, 2015–2025
Table 58: Key Clinical Trials of Gilead’s Epclusa
Table 59: Product Profile – Epclusa
Table 60: Efficacy of Epclusa – SVR12, Key Phase III Trials
Table 61: Safety of Epclusa – Most Common AEs
Table 62: Epclusa SWOT Analysis, 2016
Table 63: Global Sales Forecasts ($m) for Epclusa, 2015–2025
Table 64: Sovaldi – Clinical Trials Supporting Regulatory Approval
Table 65: Product Profile – Sovaldi
Table 66: Efficacy of Sovaldi – SVR12, Key Phase III Trials
Table 67: Safety of Sovaldi – Most Common AEs
Table 68: Sovaldi SWOT Analysis, 2016
Table 69: Global Sales Forecast ($m) for Sovaldi, 2015–2025
Table 70: Daklinza – Key Clinical Trials Supporting Regulatory Approval
Table 71: Product Profile – Daklinza
Table 72: Efficacy of Daklinza – SVR12, Key Phase IIb and III Trials
Table 73: Safety of Daklinza – Most Common AEs
Table 74: Daklinza SWOT Analysis, 2016
Table 75: Global Sales Forecast ($m) for Daklinza, 2015–2025
Table 76: Olysio – Key Clinical Trials Supporting Regulatory Approval
Table 77: Product Profile – Olysio
Table 78: Efficacy of Olysio – SVR12, Key Phase III and Phase II Trials
Table 79: Safety of Olysio – Most Common AEs in Clinical Trials
Table 80: Olysio SWOT Analysis, 2016
Table 81: Global Sales Forecasts ($m) for Olysio, 2015–2025
Table 82: Product Profile – Pegasys
Table 83: Product Profile – PegIntron
Table 84: Efficacy of Pegasys with or without Ribavirin Compared with Interferon Alfa-2b
Table 85: Efficacy of PegIntron Compared With Interferon Alfa-2b
Table 86: Pegasys and PegIntron SWOT Analysis, 2016
Table 87: Global Sales Forecast ($m) for Pegasys, 2015–2025
Table 88: Global Sales Forecast ($m) for PegIntron, 2015–2025
Table 89: Ribavirin SWOT Analysis, 2016
Table 90: Global Sales Forecast ($m) for Copegus, 2015–2025
Table 91: Global Sales Forecast ($m) for Rebetol, 2015–2025
Table 92: Summary of Other Branded DAAs, 2016
Table 93: Unmet Needs and Opportunities in Chronic Hepatitis C
Table 94: Hepatitis C Virus Infection – Late-Stage Pipeline, 2016
Table 95: Key Clinical Trials of Gilead’s Sofosbuvir/Velpatasvir/Voxilaprevir Combination
Table 96: Product Profile – Sofosbuvir/Velpatasvir/Voxilaprevir
Table 97: Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Phase II Clinical Trials
Table 98: Sofosbuvir/Velpatasvir/Voxilaprevir SWOT Analysis, 2016
Table 99: Global Sales Forecast ($m) for Sofosbuvir/Velpatasvir/Voxilaprevir, 2015–2025
Table 100: Phase III Clinical Trials of AbbVie’s Glecaprevir/Pibrentasvir Combination
Table 101: Product Profile – Glecaprevir/Pibrentasvir
Table 102: Efficacy of Glecaprevir/Pibrentasvir in Phase II Trials
Table 103: Most Common AEs of Glecaprevir/Pibrentasvir in Phase II Trials
Table 104: Glecaprevir/Pibrentasvir SWOT Analysis, 2016
Table 105: Global Sales Forecast ($m) for Glecaprevir/Pibrentasvir, 2015–2025
Table 106: Phase III Clinical Trials of BMS’s Asunaprevir/Beclabuvir/Daclatasvir
Table 107: Product Profile – Asunaprevir/Beclabuvir/Daclatasvir
Table 108: Efficacy of Asunaprevir/Beclabuvir/Daclatasvir in Phase III Clinical Trials
Table 109: Efficacy of Asunaprevir/Beclabuvir/Daclatasvir in Japanese Patients
Table 110: Asunaprevir/Beclabuvir/Daclatasvir SWOT Analysis, 2016
Table 111: Global Sales Forecast ($m) for Asunaprevir/Beclabuvir/Daclatasvir, 2015–2025
Table 112: On-Going Phase II Clinical Trials of MK-3682A and MK-3682B
Table 113: Product Profile – MK-3682A and MK-3682B
Table 114: Efficacy of MK-3682A and MK-3682B in Phase II Trials
Table 115: MK-3682A and MK-3682B SWOT Analysis, 2016
Table 116: Global Sales Forecasts ($m) for MK-3682A and MK-3682B, 2015–2025
Table 117: Phase II Clinical Trials involving Achillion and Janssen’s Odalasvir
Table 118: Product Profile – AL-335/odalasvir/simeprevir
Table 119: AL-335/Odalasvir/Simeprevir SWOT Analysis, 2016
Table 120: Global Sales Forecast ($m) for AL-335/Odalasvir/Simeprevir, 2015–2025
Table 121: Other Products in Clinical Development for HCV Infection, 2016
Table 122: Clinical Development outside 9MM, 2016
Table 123: Key Companies in the HCV Marketplace in the 9MM, 2016
Table 124: Gilead’s HCV Portfolio Assessment, 2016
Table 125: AbbVie’s HCV Portfolio Assessment, 2016
Table 126: Merck’s HCV Portfolio Assessment, 2016
Table 127: Janssen’s HCV Portfolio Assessment, 2016
Table 128: BMS’ HCV Portfolio Assessment, 2016
Table 129: Roche’s HCV Portfolio Assessment, 2016
Table 130: Regulus’ HCV Portfolio Assessment, 2016
Table 131: Presidio’s HCV Portfolio Assessment, 2016
Table 132: Trek Therapeutics’ HCV Portfolio Assessment, 2016
Table 133: Global (9MM) Sales Forecast ($m) for Hepatitis C, 2015–2025
Table 134: 9MM Chronic Hepatitis C Market – Drivers and Barriers, 2015-2025
Table 135: US Sales Forecast ($m) for Hepatitis C, 2015–2025
Table 136: Key Events Impacting Sales for Chronic Hepatitis C in the US, 2015–2025
Table 137: Chronic Hepatitis C Market – Drivers and Barriers in the US, 2015–2025
Table 138: 5EU Sales Forecast ($m) for Hepatitis C, 2015–2025
Table 139: Key Events Impacting Sales for Chronic Hepatitis C in the 5EU, 2015–2025
Table 140: Chronic Hepatitis C Market – Drivers and Barriers in the 5EU, 2015–2025
Table 141: France Sales Forecast ($m) for Hepatitis C, 2015–2025
Table 142: Key Events Impacting Sales for Chronic Hepatitis C in France, 2015–2025
Table 143: Chronic Hepatitis C Market – Drivers and Barriers in France, 2015–2025
Table 144: Germany Sales Forecasts ($m) for Hepatitis C, 2015–2025
Table 145: Key Events Impacting Sales for Chronic Hepatitis C in Germany, 2015–2025
Table 146: Chronic Hepatitis C Market – Drivers and Barriers in Germany, 2015–2025
Table 147: Italy Sales Forecast ($m) for Hepatitis C, 2015–2025
Table 148: Key Events Impacting Sales for Chronic Hepatitis C in Italy, 2015–2025
Table 149: Chronic Hepatitis C Market – Drivers and Barriers in Italy, 2015–2025
Table 150: Spain Sales Forecast ($m) for Hepatitis C, 2015–2025
Table 151: Key Events Impacting Sales for Chronic Hepatitis C in Spain, 2015–2025
Table 152: Chronic Hepatitis C Market – Drivers and Barriers in Spain, 2015–2025
Table 153: UK Sales Forecasts ($m) for Hepatitis C, 2015–2025
Table 154: Key Events Impacting Sales for Chronic Hepatitis C in the UK, 2015–2025
Table 155: Chronic Hepatitis C Market – Drivers and Barriers in the UK, 2015–2025
Table 156: Japan Sales Forecast ($m) for Hepatitis C, 2015–2025
Table 157: Key Events Impacting Sales for Chronic Hepatitis C in Japan, 2015–2025
Table 158: Chronic Hepatitis C Market – Drivers and Barriers in Japan, 2015–2025
Table 159: Brazil Sales Forecast ($m) for Hepatitis C, 2015–2025
Table 160: Key Events Impacting Sales for Chronic Hepatitis C in Brazil, 2015–2025
Table 161: Chronic Hepatitis C Market – Drivers and Barriers in Brazil, 2015–2025
Table 162: China Sales Forecast ($m) for Hepatitis C, 2015–2025
Table 163: Key Events Impacting Sales for Chronic Hepatitis C in China, 2015–2025
Table 164: Chronic Hepatitis C Market – Drivers and Barriers in China, 2015–2025
Table 165 Key Historical and Projected Launch Dates for Chronic Hepatitis C
Table 166 Key Historical and Projected Patent Expiry Dates for Chronic Hepatitis C
Table 167: High Prescribers Surveyed